Share this article
NEW YORK, May 20, 2021 /PRNewswire/
RenBio, a privately-held, preclinical biotechnology company developing novel, best-in-class antiviral antibody therapeutics and a next-generation antibody delivery platform, today announced that it has completed a $24 million Series A financing, led by Taiwan-based Ruentex Group. The company has also signed a license agreement with Columbia University, giving RenBio the exclusive worldwide development and commercialization rights to a novel bispecific antibody (RB-100) for COVID-19 that was developed in the lab of David D. Ho, M.D. of Columbia University and targets two distinct sites on the spike of SARS-CoV-2. In preclinical studies, RB-100 demonstrated robust antiviral activity against SARS-CoV-2 variants that have recently emerged from the U.K. (B.1.1.7), South Africa (B.1.351), Brazil (P.1), California (B.1.427 and B.1.429), and New York City (B.1.526).
RenBio Completes $24 Million Series A Financing and Licenses Novel SARS-CoV-2 Bispecific Antibody from Columbia University
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Jennifer Clement Taymor y Spielberg trabajan obras para el cine
milenio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from milenio.com Daily Mail and Mail on Sunday newspapers.
ThermoGenesis Holdings Announces Financial Results for the First Quarter Ended March 31, 2021 and Provides Corporate Update
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET
News provided by
Share this article
Share this article
RANCHO CORDOVA, Calif., May 13, 2021 /PRNewswire/ ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the first quarter ended March 31, 2021 and provided a corporate strategic update.
First Quarter Achievements:
On February 3, 2021, the Company announced that it completed the development process for its new PXP®-LAVARE System and submitted a Letter to File with an updated device listing to the U.S. Food and Drug Administration (FDA). The GMP compliant PXP-LAVARE allows for fast, automated, and reliable cell washing. It is an optional cell reformulation accessory designed for use along with the P